γδ T cell therapy for the treatment of non-small cell lung cancer

Translational Lung Cancer Research

Volumn 3, Issue 1, 2014, Pages 23-33

  Kakimi, Kazuhiro ^a   Matsushita, Hirokazu ^a   Murakawa, Tomohiro ^a   Nakajima, Jun ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Adoptive transfer; Cell therapy; Non small cell lung cancer (NSCLC); T cells

Indexed keywords

ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); EX VIVO STUDY; FEASIBILITY STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IN VIVO STUDY; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

EID: 84938605228     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.11.01     Document Type: Review

References (38)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Bonanno L, Favaretto A, Rugge M, et al. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs 2011;71:2231-46.
3. Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 2009;65:1-8.
4. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000;18:975-1026.
5. Pont F, Familiades J, Déjean S, et al. The gene expression profile of phosphoantigen-specific human γδ T lymphocytes is a blend of αβ T-cell and NK-cell signatures. Eur J Immunol 2012;42:228-40.
6. Hayday AC. Gammadelta T cells and the lymphoid stresssurveillance response. Immunity 2009;31:184-96.
7. Ferrarini M, Ferrero E, Dagna L, et al. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002;23:14-8.
8. Narayan K, Sylvia KE, Malhotra N, et al. Intrathymic programming of effector fates in three molecularly distinct γδ T cell subtypes. Nat Immunol 2012;13:511-8.
9. Riganti C, Massaia M, Davey MS, et al. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators? Eur J Immunol 2012;42:1668-76.
10. Modlin RL, Pirmez C, Hofman FM, et al. Lymphocytes bearing antigen-specific gamma delta T-cell receptors accumulate in human infectious disease lesions. Nature 1989;339:544-8.
11. Tanaka Y, Morita CT, Tanaka Y, et al. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995;375:155-8.
12. Eberl M, Hintz M, Reichenberg A, et al. Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett 2003;544:4-10.
13. Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-58.
14. Thurnher M, Nussbaumer O, Gruenbacher G. Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 2012;18:3524-31.
15. Champagne E. γδ T cell receptor ligands and modes of antigen recognition. Arch Immunol Ther Exp (Warsz) 2011;59:117-37.
16. Groh V, Steinle A, Bauer S, et al. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:1737-40.
17. Gomes AQ, Martins DS, Silva-Santos B. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 2010;70:10024-7.
18. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 1999;340:737-8.
19. Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 2003;102:200-6.
20. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007;67:7450-7.
21. Bennouna J, Levy V, Sicard H, et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors. Cancer Immunol Immunother 2010;59:1521-30.
22. Sicard H, Ingoure S, Luciani B, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol 2005;175:5471-80.
23. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and antitumor effects of adoptive immunotherapy using gammadelta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2007;56:469-76.
24. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57:1599-609.
25. Kobayashi H, Tanaka Y, Yagi J, et al. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 2011;60:1075-84.
26. Nicol AJ, Tokuyama H, Mattarollo SR, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 2011;105:778-86.
27. Abe Y, Muto M, Nieda M, et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009;37:956-68.
28. Noguchi A, Kaneko T, Kamigaki T, et al. Zoledronateactivated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Cytotherapy 2011;13:92-7.
29. Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842-56.
30. Kondo M, Izumi T, Fujieda N, et al. Expansion of human peripheral blood γδ T cells using zoledronate. J Vis Exp 2011;(55). pii: 3182.
31. Ferrarini M, Heltai S, Pupa SM, et al. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors. J Natl Cancer Inst 1996;88:436-41.
32. Shojaei H, Oberg HH, Juricke M, et al. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 2009;69:8710-7.
33. Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37:1191-7.
34. Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J Immunother 2011;34:202-11.
35. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4244-52.
36. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
37. Ménard C, Martin F, Apetoh L, et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57:1579-87.
38. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.